Galecto Announces Pricing of Initial Public Offering

by Ysios Capital

4 years ago
fibrotic, Galecto, biotechnology, cancer, GLTO, biological processes

Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company developing therapeutics that are designed to target the biological processes that lie at the heart of fibrosis and impact a broad r...

SparingVision Raises €44.5 Million in a round led by 4BIO Capital and UPMC Enterprises, and included Jeito Capital and Ysios Capital

by Ysios Capital

4 years ago
retinitis pigmentosa, SparingVision, 4BIO Capital, UPMC Enterprises, Jeito Capital, Ysios Capital, Bpifrance, Foundation Fighting Blindness

SparingVision (“the Company”), a genomic medicine company focused on ocular diseases, today announces a €44.5 million financing round. The round was led by 4BIO Capital (“4BIO”) and UPMC Ent...

Galecto Raises $64 Million to Accelerate Development of Clinical Pipeline

by Ysios Capital

4 years ago
Eir Ventures, Galecto, Clinical Pipeline, fibrosis, cancer, Soleus Capital

Funds will support preparations for potential EU conditional approval of GB0139 in IPF and multiple new Phase 2 clinical trials

Minoryx Therapeutics, participated by Ysios and Caixa Capital Risc, and Sperogenix Therapeutics enter into an exclusive license agreement

by Ysios Capital

4 years ago
adrenoleucodistrofia, leriglitazona, Minoryx Therapeutics, Ysios Capital, Caixa Capital Risc, Sperogenix Therapeutics

Sperogenix Therapeutics, a platform company dedicated to developing and commercializing rare disease therapeutics in China, and Minoryx Therapeutics, a company that specializes in the development of i...

LAVA Therapeutics Announces $83 million Series C Financing to Advance Novel Immuno-Oncology Programs

by Ysios Capital

4 years ago
LAVA Therapeutics, Ysios Capital, cancer, pharmaceutical, platform

LAVA Therapeutics, a biotech company pioneering the development of bispecific antibodies to engage gamma-delta T cells for cancer therapies, today announced the closing of an oversubscribed $83 millio...

ProteoDesign announces new Investment led by Ysios Capital and rebrands as Splice Bio

by Ysios Capital

4 years ago
Caixa Capital Risc, Asabys Partners, ProteoDesign, Splice Bio, gene therapies, platform

Splice Bio, a biotech company based on technology developed in the Muir Lab at Princeton University, announced today a new investment into the Company led by Ysios Capital and joined by Asabys Partner...

VarmX raises €32 million in Series B round led by Ysios Capital and INKEF Capital

by Ysios Capital

4 years ago
INKEF Capital, Lundbeckfonden Ventures, LSP, BioGeneration Ventures, InnovationQuarter, VarmX, Ysios Capital, drugs, anticoagulation, thrombosis

The oversubscribed round was co-led by Ysios Capital and INKEF Capital; Lundbeckfonden Ventures and LSP joined the syndicate. Founding investor, BioGeneration Ventures (BGV) and the regional economic ...

Ona Therapeutics raises €30M in Series A financing

by Ysios Capital

4 years ago
cancer, Ona Therapeutics, Sabadell Asabys, Alta Life Sciences, Ysios Capital, FundPlus, BPI France

Ona Therapeutics, which is focused on the discovery and development of therapeutic biologics to treat metastatic cancer, announces today the closing of a €30 million Series A financing, with partici...

Ysios Capital presents its third fund of € 200M

by Ysios Capital

4 years ago
Ysios BioFund III, Ysios Capital, invest, drugs

Ysios Capital, a leading biotechnology venture capital firm in Spain, today announced its third fund, Ysios BioFund III, with a committed amount of € 155M and a final target size of € 200M.

AM-Pharma Raises €116m [$133m] to Conduct Pivotal Phase III Trial of recAP in Acute Kidney Injury

by Ysios Capital

5 years ago
Ysios Capital, AM-Pharma, acute kidney injury, drug

AM-Pharma B.V. (‘AM-Pharma, the Company’), a clinical stage biopharmaceutical company, leading in the development of a treatment for acute kidney injury (AKI) with its innovative recombinant human...

Sanifit announces €72.2M ($80.9M) financing in Spain’s largest private biotech fundraise

by Ysios Capital

5 years ago
Columbus, Alta, Caixa Capìtal Risc, Sanifit, private, biotech, frundaise

Sanifit, a clinical-stage biopharmaceutical company focused on treatments for progressive vascular calcification disorders, today announced the completion of a €72.2 million (USD 80.9 million) total...

Aura Biosciences Completes $40 Million Series D Financing

by Ysios Capital

5 years ago
Ysios Capital, Aura Biosciences, Lundbeckfonden, Advent Life Sciences, Arix Bioscience, Chiesi Ventures, Columbus Venture Partners

Aura Biosciences, a leader in the development of novel targeted therapies in ocular oncology, today announced that it closed a $40 million Series D financing. New investor Medicxi led the round, with